Dysregulation of the mTOR pathway is a common feature in many types of cancer. Aberrant activation of mTOR signaling promotes uncontrolled cell proliferation, survival, and metabolic reprogramming, all of which are hallmarks of cancer. Mutations or alterations in upstream regulators such as PI3K, AKT, and TSC1/TSC2 can lead to persistent mTOR activation.
